FAQ

Carcinoma in situ of esophagus

Known as: Severe Esophageal Dysplasia, stage 0 esophageal carcinoma in situ, Esophageal Carcinoma in situ AJCC v7 
Stage 0 includes: For squamous cell carcinoma: Tis (HGD), N0, M0, G1, GX, Tumor location: Any. For adenocarcinoma: Tis (HGD), N0, M0, G1, GX. Tis… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
02420122018

Related topics

Related topics

16 relations
Benign neoplasm of esophagusCarcinoma in SituEpithelial CellsEpithelium
(More)

Broader (1)

Esophageal Diseases

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
Carcinoma in situ of esophagus
cancer cell
Esophagus
Gastrointestinal system
Epithelial Cells
abnormal cellular structure or growth

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
OBJECTIVE We examined whether androgen receptor splice variant 7 (AR-V7) in circulating tumor cell(CTC)clusters can be used to… (More)
Is this relevant?
Review
2018
Review
2018
CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.
INTRODUCTION Prostate cancer is a highly heterogeneous disease, with remarkably different prognosis across all stages. Increased… (More)
Is this relevant?
2017
2017
Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.
PURPOSE We evaluated the association of PSA and androgen receptor splice variant-7 (AR-V7) transcript levels in patients' blood… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2017
2017
DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7
Constitutively active AR-V7, one of the major androgen receptor (AR) splice variants lacking the ligand-binding domain, plays a… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.
BACKGROUND Overexpression of the androgen receptor (AR) splice variant 7 (AR-V7) has recently been reported to be associated with… (More)
Is this relevant?
2016
2016
Prostate cancer: AR-V7 status in CTCs is a treatment-specific biomarker
 
Is this relevant?
2016
2016
Prostate cancer: Exosomal AR-V7 is a marker of hormonal therapy resistance
 
Is this relevant?
2014
2014
Prostate cancer: Predicting resistance—AR-V7 is a potential biomarker
This study prospectively enrolled 62 patients who were beginning treatment for mCRPC; 31 men were assigned to receive 160 mg… (More)
Is this relevant?
2013
2013
The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.
BACKGROUND The androgen receptor (AR) AR-V7 splice isoform is a constitutively active outlaw transcription factor. Transition of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression.
PURPOSE AR-V7, a ligand independent splice variant of androgen receptor, may support the growth of castration resistant prostate… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?